Muscarinic antagonist binding to intact rat thymocytes

Update on PET Tracer Development for Muscarinic Acetylcholine Receptors

The muscarinic cholinergic system regulates peripheral and central nervous system functions, and, thus, their potential as a therapeutic target for several neurodegenerative diseases is undoubted. A clinically applicable positron emission tomography (PET) tracer would facilitate the monitoring of disease progression, elucidate the role of muscarinic acetylcholine receptors (mAChR) in disease development and would aid to clarify the diverse natural functions of mAChR regulation throughout the nervous system, which still are largely unresolved. Still, no mAChR PET tracer has yet found broad clinical application, which demands mAChR tracers with improved imaging properties. This paper reviews strategies of mAChR PET tracer design and summarizes the binding properties and preclinical evaluation of recent mAChR tracer candidates. Furthermore, this work identifies the current major challenges in mAChR PET tracer development and provides a perspective on future developments in this area of research.

New approaches to the treatment of pemphigus

In pemphigus vulgaris, treatment with systemic glucocorticosteroids is life saving; it may, however, cause severe side effects, including death. A patient with pemphigus vulgaris and myasthenia gravis was treated for approximately five years with the cholinomimetic Mestinon (pyridostigmine bromide), Imuran (azathioprine), and a topical corticosteroid gel before the need to introduce systemic glucocorticosteroids. Because activation of keratinocyte acetylcholine receptors also has been shown to abolish pemphigus IgG-induced acantholysis in cultured keratinocyte monolayers, a clinical trial of Mestinon was initiated in patients with active pemphigus vulgaris, pemphigus foliaceus, and paraneoplastic autoimmune multiorgan syndrome (also known as paraneoplastic pemphigus). First results indicate that nonsteroidal treatment of pemphigus is possible. Mestinon may be used to slow down progression of the disease and to treat mild cases with chronic lesions on limited areas. Stimulation of the keratinocyte- acetylcholine axis may lead to a therapeutic effect through any of the following mechanisms: (1) stimulating keratinocyte cell-to-cell attachment; (2) accelerating reepithelialization; and (3) competing with the disease-causing pemphigus antibodies, preventing them from attachment to keratinocytes. Glucocorticosteroids and various types of steroid-sparing drugs used to treat pemphigus exhibit cholinergic side effects, including effects on expression and function of keratinocyte adhesion molecules, that are very similar to those produced by the cholinomimetic drugs. Further elucidation of the mechanisms underlying therapeutic efficacy of antiacantholytics may shed light on the immunopharmacological mechanisms of pemphigus antibody-induced acantholysis.

Muscarinic cholinergic receptor subtypes in the pigeon bursa of Fabricius: a radioligand binding and autoradiographic study

The pharmacological profile and the anatomical localisation of muscarinic cholinergic receptor subtypes were studied in the pigeon bursa of Fabricius, using radioligand binding and autoradiographic techniques with [3H]quinuclidinyl benzilate (QNB) as a ligand. [3H]QNB was specifically bound to sections of bursa of Fabricius. The binding was time-, temperature- and concentration-dependent. The dissociation constant was 0.31 +/- 0.02 nM, and the maximum density of binding sites averaged 38 +/- 2.5 fmol/mg protein. The pharmacological profile of [3H]QNB binding to sections of pigeon bursa of Fabricius was consistent with the labelling of M2, M3 and M4 muscarinic receptor subtypes. Light microscope autoradiography showed the localisation of [3H]QNB binding sites in the medulla, in follicular septa, in the cortico-medullary border and in lesser amounts in the cortical layer. The functional significance of these receptors should be clarified in future studies.

Nicotinic receptors of rat lymphocytes during adjuvant polyarthritis

Resting rat lymphocytes and thymocytes express specific [3H]nicotine binding sites with Kd values 7.5 and 10 nM, respectively. Resting T lymphocytes express 5-7 times as many binding sites (1,500/cell) as do unfractionated thymocytes (250/cell), suggesting that only a subset of thymocytes express nicotinic binding sites. Neither macrophages nor B cells bear nicotinic receptors. [3H]nicotine binding to lymphocytes is competitively inhibited in the presence of the cholinergic agonist carbamylcholine with IC50 = 100 microM. The number of receptors expressed on draining lymph node lymphocytes is upregulated during the course of adjuvant induced polyarthritis: maximum of [3H]nicotine binding is observed at day 21 of the disease with a subsequent decline reaching basal level at day 36. These results show the presence of [3H]nicotine binding sites on T lymphocytes and suggest their involvement in the later immune phase of adjuvant induced polyarthritis.